Wspolczesna Onkologia-Contemporary Oncology

Scope & Guideline

Transforming Oncology Through Cutting-Edge Research

Introduction

Immerse yourself in the scholarly insights of Wspolczesna Onkologia-Contemporary Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageMulti-Language
ISSN1428-2526
PublisherTERMEDIA PUBLISHING HOUSE LTD
Support Open AccessYes
CountryPoland
TypeJournal
Convergefrom 2005 to 2024
AbbreviationWSPOLCZESNA ONKOL / Wspolczesna Onkol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressKLEEBERGA 2, POZNAN 61-615, POLAND

Aims and Scopes

Wspolczesna Onkologia-Contemporary Oncology is dedicated to advancing the understanding and treatment of various cancers through innovative research and clinical studies. The journal emphasizes the integration of basic science with clinical applications, aiming to provide insights that can enhance patient care and therapeutic efficacy.
  1. Clinical Oncology Research:
    The journal focuses on clinical studies that evaluate treatment outcomes, safety profiles, and the efficacy of various cancer therapies, including chemotherapy, immunotherapy, and targeted therapies.
  2. Molecular and Cellular Oncology:
    Research on the molecular mechanisms underlying cancer development, progression, and metastasis is a core focus, including studies on gene expression, signaling pathways, and the tumor microenvironment.
  3. Translational Research:
    The journal supports translational research that bridges laboratory findings with clinical applications, aiming to translate scientific discoveries into effective treatment strategies for cancer patients.
  4. Patient-Centered Outcomes:
    There is a strong emphasis on studies that assess the psychosocial aspects of cancer care, including patient satisfaction, quality of life, and coping mechanisms, reflecting a holistic approach to oncology.
  5. Innovative Diagnostic Techniques:
    The journal publishes research on novel diagnostic methods, including imaging techniques and biomarker discovery, which are crucial for early detection and personalized treatment strategies.
Recent publications in Wspolczesna Onkologia-Contemporary Oncology indicate a shift towards several emerging themes that address contemporary challenges in oncology and reflect advancements in cancer research.
  1. Immunotherapy and Targeted Therapies:
    There is a growing trend towards research on immunotherapy and targeted treatments, reflecting the rapid advancements in these areas and their significance in improving patient outcomes.
  2. Molecular Profiling and Biomarkers:
    Emerging studies focus on the identification and validation of molecular biomarkers for cancer diagnosis, prognosis, and treatment responses, indicating a trend towards personalized medicine.
  3. Artificial Intelligence and Machine Learning in Oncology:
    The incorporation of AI and machine learning techniques for cancer detection, diagnosis, and treatment planning is gaining traction, highlighting the role of technology in modern oncology.
  4. Psycho-Oncology and Patient Wellbeing:
    Research addressing the psychosocial dimensions of cancer care, including the mental health of patients and their families, is increasingly prevalent, emphasizing the importance of a holistic approach to treatment.
  5. Real-World Evidence and Outcomes Research:
    There is a notable increase in studies utilizing real-world data to assess treatment outcomes and patient experiences, reflecting a shift towards understanding the effectiveness of interventions in everyday clinical practice.

Declining or Waning

Over the years, certain themes within Wspolczesna Onkologia-Contemporary Oncology have seen a decrease in emphasis, reflecting shifts in research priorities and the evolving landscape of oncology.
  1. Traditional Chemotherapy Studies:
    While still relevant, there has been a noticeable decline in studies focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards personalized and targeted therapies.
  2. Epidemiological Studies:
    Research that primarily focuses on cancer epidemiology and incidence trends has become less prominent, likely due to a growing interest in molecular and therapeutic research.
  3. Case Reports and Single-Center Experiences:
    The frequency of case reports and single-center studies has decreased, suggesting a shift towards larger, multicenter studies that provide more generalizable results.
  4. Basic Science Research:
    There is a waning focus on basic science research unrelated to clinical applications, as the journal prioritizes studies that integrate laboratory findings with clinical implications.
  5. Complementary and Alternative Medicine:
    Interest in studies exploring complementary and alternative therapies appears to be declining, possibly due to a stronger emphasis on evidence-based conventional treatments.

Similar Journals

Cancer Cell International

Exploring New Horizons in Cancer Treatment
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

Journal of Cancer

Connecting researchers to transform cancer care.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

ANTICANCER RESEARCH

Empowering Discovery in Anticancer Science
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Journal of Bone Oncology

Unlocking Innovations in Bone Cancer Treatment
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Catalyzing Discoveries in Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Exploring Breakthroughs in Cancer Science and Patient Care.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Cancers

Fostering collaboration in the fight against cancer.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Molecular and Clinical Oncology

Uncovering the molecular secrets of oncology.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

INTERNATIONAL JOURNAL OF ONCOLOGY

Pioneering innovative practices in cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

LANCET ONCOLOGY

Discovering innovative solutions for complex oncology challenges.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.